Zur inhalativen Antibiotika-Therapie bei Patienten mit zystischer Fibrose und Pseudomonas-Befall [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]

Détails

ID Serval
serval:BIB_C39D1DD2A9EA
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Zur inhalativen Antibiotika-Therapie bei Patienten mit zystischer Fibrose und Pseudomonas-Befall [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]
Périodique
Schweizerische Medizinische Wochenschrift
Auteur⸱e⸱s
Mordasini C., Aebischer C.C., Schoch O.D.
ISSN
0036-7672
Statut éditorial
Publié
Date de publication
1997
Peer-reviewed
Oui
Volume
127
Numéro
21
Pages
905-910
Langue
allemand
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Treating chronic Pseudomonas infection of the bronchial tree is a very important part of the treatment strategy in patients with cystic fibrosis. There are only a few antibiotics which are effective against pseudomonas. Many of them soon lead to bacterial resistance (e.g. fluoro-quinolones). Inhaling antibiotics produces high sputum concentrations and low systemic toxicity. Tolerance is good and resistance rare. Several clinical studies, some of them doubleblind placebo controlled, have shown a positive effect of inhaled antibiotics on symptoms, on frequency of necessary i.v. therapies and also on pulmonary function. Most commonly aminoglycosides (tobramycin) and colistin, which is not yet registered in Switzerland, are used. The main indication is chronic therapy of Pseudomonas infection.
Mots-clé
Administration, Inhalation, Anti-Bacterial Agents, Bronchitis, Colistin, Cystic Fibrosis, Humans, Microbial Sensitivity Tests, Pseudomonas Infections, Tobramycin
Pubmed
Web of science
Création de la notice
28/01/2008 11:01
Dernière modification de la notice
20/08/2019 16:38
Données d'usage